Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Share-based Compensation: 2022-2025

Historic Share-based Compensation for Praxis Precision Medicines (PRAX) over the last 4 years, with Sep 2025 value amounting to $7.4 million.

  • Praxis Precision Medicines' Share-based Compensation fell 40.10% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 million, marking a year-over-year decrease of 15.41%. This contributed to the annual value of $41.4 million for FY2024, which is 66.39% up from last year.
  • According to the latest figures from Q3 2025, Praxis Precision Medicines' Share-based Compensation is $7.4 million, which was down 4.16% from $7.8 million recorded in Q2 2025.
  • In the past 5 years, Praxis Precision Medicines' Share-based Compensation ranged from a high of $14.5 million in Q1 2024 and a low of $5.7 million during Q4 2023.
  • For the 3-year period, Praxis Precision Medicines' Share-based Compensation averaged around $8.2 million, with its median value being $7.6 million (2023).
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 115.72% in 2024, then crashed by 40.10% in 2025.
  • Praxis Precision Medicines' Share-based Compensation (Quarterly) stood at $6.4 million in 2022, then dropped by 10.05% to $5.7 million in 2023, then skyrocketed by 49.76% to $8.6 million in 2024, then tumbled by 40.10% to $7.4 million in 2025.
  • Its last three reported values are $7.4 million in Q3 2025, $7.8 million for Q2 2025, and $8.8 million during Q1 2025.